Forecast

The analysts' average price target is €18.08 (+24.78%). The median is €18.08 (+24.78%).

Buy	4
Hold	8
Sell	1

News Go to news feed

Viatris raises guidance after Q2 growth and gains FDA approval for contraceptive patch

Viatris reported Q2 revenue up about 4.9% year over year and management raised fiscal 2026 guidance across key metrics. Billionaire-led funds held stakes in the stock as it traded near $16, up ~33% year-to-date. The FDA approved the once-weekly Gwyn Lo contraceptive patch, a fast-acting meloxicam formulation is under review and two late-stage trials (selatogrel and cenerimod) will report in early fiscal 2027. Valuation looks attractive (forward non-GAAP P/E ~6.6, EV/EBITDA ~7) but tariff risk and looming changes to generic exemptions in 2028 pose material downside for its import-reliant portfolio. » More on finance.yahoo.com
Viatris beats Q2 expectations and raises full-year outlook

Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » More on de.investing.com
Viatris receives FDA approval for once-weekly contraceptive patch Gwyn Lo

The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, VIATRIS INC. O.N. has already paid €0.20 in dividends. The last payout was in June.

Financials

In the last quarter, VIATRIS INC. O.N. had revenue of €3.29B and net profit of -€104.09M

(EUR)	June 2026	YoY
Revenue	3.29B	8.31%
Gross profit	1.28B	12.85%
Net profit	-104.09M	2,567.20%
EBITDA	572.43M	16.77%

Fundamentals

Metric	Value
Market capitalization	€16.93B
Number of shares	1.16B
52-week high/low	€15.83 - €8.12
Dividend yield	2.84%
Dividends TTM	€0.41
Next dividend	€0.10
Beta	0.88
P/E ratio	-46.89
PEG ratio	-3.21
P/B ratio	1.38
P/S ratio	1.33

Company profile

Viatris Inc. ist ein weltweit tätiges Gesundheitsunternehmen. Das Unternehmen ist in vier Segmenten tätig: Developed Markets, Greater China, JANZ und Emerging Markets. Es bietet verschreibungspflichtige Markenmedikamente, Generika, komplexe Generika, Biosimilars und aktive pharmazeutische Inhaltsstoffe (APIs). Das Unternehmen bietet Medikamente in verschiedenen therapeutischen Bereichen an, darunter nichtübertragbare und Infektionskrankheiten, Biosimilars in den Bereichen Onkologie, Immunologie, Endokrinologie, Augenheilkunde und Dermatologie sowie APIs für die Bereiche Antibiotika, Mittel für das zentrale Nervensystem, Antihistaminika/Antiasthmatika, Herz-Kreislauf-Medikamente, Virostatika, Antidiabetika, Antimykotika und Protonenpumpenhemmer sowie unterstützende Dienstleistungen wie Diagnosekliniken, Aufklärungsseminare und digitale Hilfsmittel, die Patienten helfen, ihre Gesundheit besser zu verwalten. Das Unternehmen bietet seine Arzneimittel in Form von festen oralen Dosen, injizierbaren Arzneimitteln, komplexen Darreichungsformen und Wirkstoffen dem Einzelhandel und Apotheken, Großhändlern und Distributoren, Kostenträgern, Versicherern und Regierungen sowie Institutionen an. Das Unternehmen vertreibt seine Produkte über pharmazeutische Großhändler/Vertriebsunternehmen, pharmazeutische Einzelhändler, institutionelle Apotheken, Versand- und E-Commerce-Apotheken sowie Spezialapotheken. Es vertreibt seine Produkte unter den Namen Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine und Yupelri; Norvasc und Viagra; AMITIZA, Lipacreon und Effexor; und Celebrex und ARV, sowie bietet Biosimilars Franchises, einschließlich Fulphila, Ogivri, Hulio und SEMGLEE. Das Unternehmen hat Kooperations- und Lizenzvereinbarungen mit Revance Therapeutics, Inc, Momenta Pharmaceuticals, Inc, Theravance Biopharma, Inc, Biocon Ltd. und Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. wurde 1961 gegründet und hat seinen Hauptsitz in Canonsburg, Pennsylvania.

Name	VIATRIS INC. O.N.
CEO	Scott Andrew Smith
Headquarters	Canonsburg, pa USA
Website	viatris.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	03/17/1980
Employees	30,000